$115 Million

Chimerix, Inc.

Follow-on Offering

Bookrunner, January 2021

Chimerix, Inc.

Chimerix is a development-stage biopharmaceutical company dedicated to accelerating the advancement of innovative medicines that make a meaningful impact in the lives of patients living with cancer and other serious diseases. Its two clinical-stage development programs are dociparstat sodium (DSTAT) and brincidofovir (BCV).